GlassScriptPhysician profile
Lester Edward Stine
NPI 1184606410
$14,327.09
in general payments reported to CMS, 2019-2025
38 companies · $2,550 in 2025
The $2,550 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,123 · 2020: $1,035 · 2021: $955 · 2022: $2,148 · 2023: $2,190 · 2024: $2,325 · 2025: $2,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,026 · Education: $40.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,026.22 |
| Education | $40.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,135.82 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,583.21 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,465.67 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,453.78 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $888.57 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $739.61 | 2019-2022 | |
| Daiichi Sankyo INC. | $730.95 | 2019-2025 | Injectafer |
| Ardelyx, INC. | $638.37 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $447.73 | 2019-2022 | |
| Qol Medical, LLC | $401.98 | 2019-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $347.17 | 2022-2025 | Dupixent |
| Celgene Corporation | $343.13 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $285.77 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $212.15 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $196.93 | 2024-2025 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $192.86 | 2019 | |
| Genzyme Corporation | $184.94 | 2022-2024 | |
| Shionogi INC | $159.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $133.48 | 2019-2023 | Dificid, Zinplava |
| Celltrion USA INC. | $131.59 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $125.79 | 2019-2023 | Linzess |
| Vivus LLC | $103.19 | 2019-2020 | |
| Organon LLC | $57.44 | 2023-2025 | Hadlima, Renflexis |
| Aimmune Therapeutics, INC. | $54.86 | 2025 | Zenpep, Vowst |
| Fresenius Kabi USA, LLC | $38.68 | 2024 | Idacio |
| Allergan, INC. | $36.06 | 2019 | |
| Mallinckrodt Hospital Products INC. | $32.79 | 2024 | Terlivaz |
| Madrigal Pharmaceuticals | $28.66 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $24.18 | 2025 | The Cologuard Plus Collection Kit |
| Alfasigma USA, INC. | $24.14 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $18.97 | 2023 | |
| Ucb, INC. | $18.57 | 2019 | |
| Redhill Biopharma INC. | $17.94 | 2020 | |
| Shire North American Group INC | $17.93 | 2019 | |
| Stryker Corporation | $15.67 | 2025 | Neptune |
| Lilly USA, LLC | $14.46 | 2025 | Omvoh |
| Evoke Pharma, INC. | $13.71 | 2025 | |
| Ferring Pharmaceuticals INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Stine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.